Products liability and "off-label" use of prescription drugs

Article Abstract:

Charging drug manufacturers with a duty to warn of all demonstrated risks associated with off-label use of a drug is the most efficient way of dealing with liability for injuries resulting from off-label drug use. The demonstrated risk approach serves to reduce social costs borne by the pharmaceutical industry while providing physicians with the freedom to prescribe drugs for off-label purposes. This approach is less costly to society than the foreseeable misuse rule and recognizes that seeking FDA approval for all uses would be cost-prohibitive for manufacturers.

United States, Drugs, Cases, Laws, regulations and rules, Pharmaceutical industry, Product liability, Prescriptions (Drugs), Products liability, Off-label prescribing, Off label prescribing

---

Tunnel vision: the war on drugs, 12 years later

Article Abstract:

The Reagan and Bush administration's war on drugs was a failure. In the first place, the effects of drug abuse pale beside those of alcohol and tobacco use. Rather than fighting drug abuse through education and treatment, Reagan and Bush chose to pour all funds into law enforcement, resulting in overcrowded prisons and court congestion so severe that federal judges no longer have enough time to devote to their civil dockets. Punishing drug users has been seen as so paramount that their human rights received little protection.

Evaluation, Political aspects, Narcotics, Control of, Narcotics control, United States. Office of National Drug Control Policy

---

Realized benefits from switching drugs

Article Abstract:

The policy of switching drugs to nonprescription status has real economic benefits, as shown by an analysis of cold and cough medicines. The study uses a model for benefits and costs and addresses the switching policy of the Food and Drug Administration. However, the success of policy to date does not justify indiscriminate switching, since there is a danger of self medication replacing necessary visits to the doctor.

Economic aspects, Nonprescription drugs, Pharmaceutical policy

Similar abstracts:

• Abstracts: Do pharmacists have a right to refuse to fill prescriptions for abortifacient drugs? Antiprogestin drugs: research and clinical use in Sweden
• Abstracts: Acceptability of mifepristone for early pregnancy interruption. Are adolescents good candidates for RU 486 as an abortion method?
• Abstracts: Industrial tribunals and the law of sex discrimination in the United Kingdom. The color complex: intraracial discrimination in the workplace
• Abstracts: Organizing worth its salt: the protected status of paid union organizers. Milking capitalism for all it's worth
• Abstracts: Equality and diversity: the eighteenth-century debate about equal protection and equal civil rights. A critical analysis of the civil penalty regime under the Credit Act 1984 (Vic.)

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.